Recent studies have found that other compounds also alleviate osteoclastogenesis and ovariectomized osteoporosis by inhibiting RANKL-induced activation of ROS and NFATc1 at relatively low doses [27, 28]. This evidence concerns the gene NFATC1 and osteoporosis.